T2DM prescriptions in India are written with particular emphasis on cost considerations leading to the relatively less frequent prescription of DPP-IV inhibitors or even lesser of SGLT-2 inhibitors, as shown in multiple prescription studies [7-9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.